Japan's Astellas reviews pipeline; aims to maximize R&D profitability

16 July 2006

Japanese drug major Astellas held an R&D meeting this month, at which it said that projects are in progress as expected. The principal R&D targets include the maximization of product value on a global basis, speedy development and launch of new products and improvement of profitability in R&D investments.

The management expressed the hope of achieving the mid-term plan formulated in November 2005 with a target operating income of 250.0 billion yen ($2.2 billion) in the fiscal year ending March 2008 (against 193.0 billion yen in that ended March 2006) through enhancement of R&D activities and cost-cutting efforts.

Priority projects

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight